Jason Zemansky
Stock Analyst
(n/a)
# 108
Out of 4,648 analysts
32
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
INSM Insmed | Maintains: Buy | $84 → $86 | $68.09 | +26.30% | 8 | Oct 9, 2024 | |
SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $18.94 | +63.67% | 3 | Aug 15, 2024 | |
RCUS Arcus Biosciences | Maintains: Neutral | $24 → $23 | $15.56 | +47.81% | 4 | Aug 9, 2024 | |
ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $2.00 | +25.00% | 5 | Jun 20, 2024 | |
CYTK Cytokinetics | Maintains: Neutral | $70 → $60 | $51.48 | +16.55% | 3 | May 23, 2024 | |
ALVR AlloVir | Downgrades: Underperform | $17 → $1 | $0.89 | +12.74% | 2 | Dec 26, 2023 | |
KURA Kura Oncology | Initiates: Buy | $31 | $17.81 | +74.06% | 1 | Aug 11, 2023 | |
HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $2.26 | +342.48% | 4 | May 12, 2023 | |
ALLK Allakos | Maintains: Buy | $145 → $155 | $1.25 | +12,300.00% | 2 | Dec 13, 2021 |
Insmed
Oct 9, 2024
Maintains: Buy
Price Target: $84 → $86
Current: $68.09
Upside: +26.30%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $18.94
Upside: +63.67%
Arcus Biosciences
Aug 9, 2024
Maintains: Neutral
Price Target: $24 → $23
Current: $15.56
Upside: +47.81%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.00
Upside: +25.00%
Cytokinetics
May 23, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $51.48
Upside: +16.55%
AlloVir
Dec 26, 2023
Downgrades: Underperform
Price Target: $17 → $1
Current: $0.89
Upside: +12.74%
Kura Oncology
Aug 11, 2023
Initiates: Buy
Price Target: $31
Current: $17.81
Upside: +74.06%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $2.26
Upside: +342.48%
Allakos
Dec 13, 2021
Maintains: Buy
Price Target: $145 → $155
Current: $1.25
Upside: +12,300.00%